TY - JOUR
T1 - Tumour maintenance is mediated by eNOS
AU - Lim, Kian Huat
AU - Ancrile, Brooke B.
AU - Kashatus, David F.
AU - Counter, Christopher M.
N1 - Funding Information:
Acknowledgements We thank J. S. Stamler for human eNOS, L. C. Cantley for TSC2S393A,T1462A, A. Baldwin for IKKaK44A, K. Walsh for FOXO3a complementary DNAs, A. D. Proia for tissue specimens, X.-F. Wang, T.-P. Yao, A. M. Pendergast, C. J. Der, A. D. Cox and M. A. Hollingsworth for discussions, and C. Ring for technical assistance. This research was supported by the NIH and NCI. C.M.C. is a Leukemia and Lymphoma Society Scholar, D.F.K. is a Leukemia and Lymphoma Society Fellow, and K.-H.L. and B.B.A. are Department of Defense Breast Cancer Research Predoctoral Scholars.
PY - 2008/4/3
Y1 - 2008/4/3
N2 - Tumour cells become addicted to the expression of initiating oncogenes like Ras, such that loss of oncogene expression in established tumours leads to tumour regression. HRas, NRas or KRas are mutated to remain in the active GTP-bound oncogenic state in many cancers. Although Ras activates several proteins to initiate human tumour growth, only PI3K, through activation of protein kinase B (PKB; also known as AKT), must remain activated by oncogenic Ras to maintain this growth. Here we show that blocking phosphorylation of the AKT substrate, endothelial nitric oxide synthase (eNOS or NOS3), inhibits tumour initiation and maintenance. Moreover, eNOS enhances the nitrosylation and activation of endogenous wild-type Ras proteins, which are required throughout tumorigenesis. We suggest that activation of the PI3K-AKT-eNOS-(wild-type) Ras pathway by oncogenic Ras in cancer cells is required to initiate and maintain tumour growth.
AB - Tumour cells become addicted to the expression of initiating oncogenes like Ras, such that loss of oncogene expression in established tumours leads to tumour regression. HRas, NRas or KRas are mutated to remain in the active GTP-bound oncogenic state in many cancers. Although Ras activates several proteins to initiate human tumour growth, only PI3K, through activation of protein kinase B (PKB; also known as AKT), must remain activated by oncogenic Ras to maintain this growth. Here we show that blocking phosphorylation of the AKT substrate, endothelial nitric oxide synthase (eNOS or NOS3), inhibits tumour initiation and maintenance. Moreover, eNOS enhances the nitrosylation and activation of endogenous wild-type Ras proteins, which are required throughout tumorigenesis. We suggest that activation of the PI3K-AKT-eNOS-(wild-type) Ras pathway by oncogenic Ras in cancer cells is required to initiate and maintain tumour growth.
UR - http://www.scopus.com/inward/record.url?scp=41649108639&partnerID=8YFLogxK
U2 - 10.1038/nature06778
DO - 10.1038/nature06778
M3 - Article
C2 - 18344980
AN - SCOPUS:41649108639
SN - 0028-0836
VL - 452
SP - 646
EP - 649
JO - Nature
JF - Nature
IS - 7187
ER -